Perrigo to acquire Paddock Labs for $540M in cash

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive agreement to acquire substantially all of the assets of Paddock Laboratories, Inc. ("Paddock"), a privately-held, Minneapolis-based manufacturer and marketer of generic pharmaceutical products for approximately $540 million in cash. Perrigo expects to receive a significant tax benefit as a result of the acquisition of Paddock's assets. The net present value of this tax benefit is estimated to be $95 million.  The acquisition is expected to close during the Company's fiscal 2011 fourth quarter pending regulatory approval.

Perrigo Chairman and CEO Joseph C. Papa stated, "This acquisition is an important next step forward in executing on our strategy to expand our specialty portfolio of generic Rx products. It adds incremental scale, as well as excellent development and manufacturing capabilities across a spectrum of niche dosage forms. It solidifies Perrigo's leading position in the extended topical space and strengthens our ability to offer new products into the market. And importantly, Paddock has a proven record for quality manufacturing with great customer service."

Key benefits of the transaction:

  • Supports Perrigo's Long-Term Growth Strategy. The transaction is aligned with the Company's strategy to further expand its generics portfolio while maintaining its strong balance sheet.
  • Complements Perrigo's Commitment to Quality. Paddock has a 30 year history of high quality manufacturing and reliability.  
  • Expands the Breadth of Perrigo's Product Offerings and adds a Strong New Product Pipeline. The transaction is expected to add more than $200 million in annual sales with over 35 products and a strong product pipeline with more than 25 ANDAs pending approval with the U.S. Food and Drug Administration.
  • Compelling Value Consistent with Stated Acquisition Criteria. Assuming a fourth quarter fiscal 2011 close, the transaction is expected to be approximately $0.05 accretive to GAAP earnings per share and, excluding $0.20 of deal-related intangible amortization, $0.25 accretive to adjusted earnings per share in fiscal year 2012. Perrigo's stated goal of Return on Invested Capital accretion is expected to be achieved in fiscal 2013. In addition, the transaction has been structured to allow the Company to preserve its strong balance sheet and financial flexibility.

Transaction terms

Pursuant to the terms of the agreement, Perrigo will acquire substantially all of the assets of Paddock for $540 million in cash. No Paddock debt or cash will be assumed in this transaction. Perrigo intends to fund the transaction using approximately $80 million of cash on hand, $310 million available per the terms of its existing bank debt agreements and $150 million from a new term loan pursuant to a commitment from Morgan Stanley, JPMorgan and Bank of America. The new term loan commitment allows for syndication of an additional $100 million which, if exercised, would reduce the amount funded under existing bank debt agreements.

Perrigo expects to receive a significant tax benefit generated from the deduction of the step-up in tax basis resulting from the acquisition of Paddock's assets. This increase in basis is expected to result in cash tax savings to Perrigo over the next 15 years. The estimated net present value of these savings is approximately $95 million. 

The proposed transaction is subject to customary closing conditions, including notification and clearance under certain antitrust statutes. There are no financing conditions to closing the acquisition agreement. Perrigo expects the transaction to close during its fourth fiscal quarter of 2011.

Mr. Papa concluded, "We are very impressed with Paddock's solid foundation and growth over the past 30 years. Bruce Paddock and his team, led by CEO Michael Graves, have built a company focused on bringing high quality products quickly to market, backed by state-of-the-art manufacturing. I am confident that this strategic acquisition will help to further grow our existing Rx business and continue to add value for our shareholders."  

SOURCE Perrigo Company

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
South Australian immunologist receives $3 million to accelerate work on Covid-19 vaccine